Tecentriq fails in Phase III IMvigor010 study as an adjuvant (after surgery) monotherapy compared to observation in people with muscle-invasive urothelial cancer .-Genentech/Roche

Roche announced that the Phase III IMvigor010 study evaluating Tecentriq (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival (DFS) compared to observation in people with muscle-invasive urothelial cancer (MIUC). Safety for Tecentriq appeared consistent with the known safety profile of the medicine, and no new safety signals were identified.

�Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is very difficult, and we are disappointed that we were not able to significantly prolong disease-free survival,� said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. �We remain committed to exploring the potential benefits of immunotherapy for more people with early cancers.� The goal in treating MIUC early is to reduce the risk of the disease recurring or spreading to other parts of the body. More treatment options following surgery are needed as approximately half of people with MIUC will develop a recurrence of their disease within 2 years of surgery.